Resultados de la búsqueda 561-570 of 2189 for GLP-1 secretion
Patients will receive VSL#3® 450B sachets probiotics, which will be provided as part of this trial, at least 3 days but preferably 1-2 weeks prior to starting ...
We hypothesize that targeting melanoma with a PD-1 (MC9324) CAR TIL therapy would capitalize on the tumor homing machinery of the TIL to drive the CAR TIL to ...
... release. Treatment of Metastatic Soft Tissue ... In the study, 122 patients will be randomized in a 1:1 ... one year later) in subjects with high-risk multiple ...
The primary objective of Part 1 of this study is to define the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of CC-220 in combination ...
Effective treatments for recurrent gynecological cancer are lacking, and there is a need for novel therapeutic options. One of the barriers to improving ...
The purpose of this study is to evaluate patterns of and changes in secretion levels of the stress hormone, cortisol and other steroid hormones (i.e. DHEA ...
Phase 1 of this study is designed to evaluate the ... Participants in both Phase 1 ... A Study of JNJ‐68284528 Out‐of‐Specification (OOS) for Commercial Release in ...
Mayo Clinic ofrece una profunda experiencia y una amplia gama de cuidados quirúrgicos a decenas de miles de personas cada año.
The purpose of phase 1 of this trial is to determine the maximum tolerated dose of temozolomide followed by selinexor in recurrent glioblastoma patients as ...
Rochester, Minn. The purpose of this study is to estimate the efficacy of LUTATHERA treatment in patients with recurrent grade 1 meningioma as measured by 6- ...
Mayo Clinic no respalda compañías ni productos. Las recaudaciones de los avisos comerciales financian nuestra misión sin fines de lucro.
Consulta estos éxitos de venta y ofertas especiales en libros y boletines informativos de Mayo Clinic Press.
¿Te gustaría hacer una donación deducible de impuestos y ser parte de una investigación de vanguardia y de una atención médica que transforma la medicina?